LAURA: Improved trend for OS benefit with osimertinib versus placebo in patients with unresectable stage III EGFR-mutant NSCLC
Lung, Respiratory and Thoracic Cancer
ELCC 2025
Related content
Lung, Respiratory and Thoracic Cancer
LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154)
Lung Cancer (Auckl)
Luo FX, Arter Z, Ou SI, Nagasaka M
doi: 10.2147/LCTT.S520833
ELCC 2025
Lung, Respiratory and Thoracic Cancer
MARIPOSA: First-line amivantamab plus lazertinib improves OS versus osimertinib in patients with EGFR-mutant advanced NSCLC
ASCO 2024
Lung, Respiratory and Thoracic Cancer
Practice-changing results with osimertinib (LAURA) and durvalumab (ADRIATIC) in patients with lung cancer
WCLC 2024
Lung, Respiratory and Thoracic Cancer
TROPION-Lung01: Datopotamab deruxtecan shows a clinically meaningful trend toward improved OS versus docetaxel in patients with NSCLC
Lung, Respiratory and Thoracic Cancer
Comparative analysis of first-line treatment in NSCLC including unresectable stage III (IIIB/IIIC) and stage IV with low PD-L1 expression: Clinical trial eligible versus ineligible patients
Lung Cancer
Hata T, Yamada T, Goto Y, Amano A, Negi Y, Watanabe S, Furuya N, Oba T, Ikoma T, Nakao A, Tanimura K, Taniguchi H, Yoshimura A, Fukui T, Murata D, Kaira K, Shiotsu S, Hibino M, Okada A, Chihara Y, Kawachi H, Kijima T, Takayama K
doi: 10.1016/j.lungcan.2025.108104
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study
★ 3
Recommended by
Dr Wolf-Dieter Janthur, Faculty Member
Ann Oncol
Lu S, Ahn MJ, Reungwetwattana T, Özgüroğlu M, Kato T, Yang JC, Huang M, Fujiki F, Inoue T, Quang LV, Sriuranpong V, Vicente D, Fuentes C, Chaudhry AA, Poole L, Armenteros Monterroso E, Rukazenkov Y, van der Gronde T, Ramalingam SS
doi: 10.1016/j.annonc.2024.08.2243
Lung, Respiratory and Thoracic Cancer
Prevalence of EGFR Mutations in Patients With Resected Stage I-III NSCLC: Results From the EARLY-EGFR Study
J Thorac Oncol
Soo RA, Reungwetwattana T, Perroud HA, Batra U, Kilickap S, Tejado Gallegos LF, Donner N, Elsayed M, Huggenberger R, Van Tu D
doi: 10.1016/j.jtho.2024.06.008
ESMO 2024
Lung, Respiratory and Thoracic Cancer
MARIPOSA: Amivantamab plus lazertinib reduced the incidence of acquired MET and EGFR resistance alterations versus osimertinib in patients with NSCLC
SPECIAL REPORT
Lung, Respiratory and Thoracic Cancer